Home > Research > Publications & Outputs > SARS-CoV-2 antibodies and breakthrough infectio...

Research

Links

Text available via DOI:

Keywords

View graph of relations

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. / Aldridge, Robert W; Yavlinsky, Alexei; Nguyen, Vincent et al.
In: Nature Communications, Vol. 13, No. 1, 4869, 18.08.2022.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Aldridge, RW, Yavlinsky, A, Nguyen, V, Eyre, MT, Shrotri, M, Navaratnam, AMD, Beale, S, Braithwaite, I, Byrne, T, Kovar, J, Fragaszy, E, Fong, WLE, Geismar, C, Patel, P, Rodger, A, Johnson, AM & Hayward, A 2022, 'SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort', Nature Communications, vol. 13, no. 1, 4869. https://doi.org/10.1038/s41467-022-32265-5

APA

Aldridge, R. W., Yavlinsky, A., Nguyen, V., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., Fragaszy, E., Fong, W. L. E., Geismar, C., Patel, P., Rodger, A., Johnson, A. M., & Hayward, A. (2022). SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. Nature Communications, 13(1), Article 4869. https://doi.org/10.1038/s41467-022-32265-5

Vancouver

Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD et al. SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. Nature Communications. 2022 Aug 18;13(1):4869. doi: 10.1038/s41467-022-32265-5

Author

Aldridge, Robert W ; Yavlinsky, Alexei ; Nguyen, Vincent et al. / SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. In: Nature Communications. 2022 ; Vol. 13, No. 1.

Bibtex

@article{263f631d49914bacae2724a727aa90b6,
title = "SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort",
abstract = "A range of studies globally demonstrate that the effectiveness of SARS-CoV-2 vaccines wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection and whether this varies by vaccine type is not well understood. Here we show that anti-S levels peak three to four weeks following the second dose of vaccine and the geometric mean of the samples is nine fold higher for BNT162b2 than ChAdOx1. Increasing anti-S levels are associated with a reduced risk of SARS-CoV-2 infection (Hazard Ratio 0.85; 95%CIs: 0.79-0.92). We do not find evidence that this antibody relationship with risk of infection varies by second dose vaccine type (BNT162b2 vs. ChAdOx1). In keeping with our anti-S antibody data, we find that people vaccinated with ChAdOx1 had 1.64 times the odds (95% confidence interval 1.45-1.85) of a breakthrough infection compared to BNT162b2. We anticipate our findings to be useful in the estimation of the protective effect of anti-S levels on risk of infection due to Delta. Our findings provide evidence about the relationship between antibody levels and protection for different vaccines and will support decisions on optimising the timing of booster vaccinations and identifying individuals who should be prioritised for booster vaccination, including those who are older, clinically extremely vulnerable, or received ChAdOx1 as their primary course. Our finding that risk of infection by anti-S level does not interact with vaccine type, but that individuals vaccinated with ChAdOx1 were at higher risk of infection, provides additional support for the use of using anti-S levels for estimating vaccine efficacy. [Abstract copyright: {\textcopyright} 2022. The Author(s).]",
keywords = "Viral Vaccines, COVID-19 Vaccines, Humans, Antibodies, Viral, SARS-CoV-2, BNT162 Vaccine, COVID-19 - prevention & control",
author = "Aldridge, {Robert W} and Alexei Yavlinsky and Vincent Nguyen and Eyre, {Max T} and Madhumita Shrotri and Navaratnam, {Annalan M D} and Sarah Beale and Isobel Braithwaite and Thomas Byrne and Jana Kovar and Ellen Fragaszy and Fong, {Wing Lam Erica} and Cyril Geismar and Parth Patel and Alison Rodger and Johnson, {Anne M} and Andrew Hayward",
year = "2022",
month = aug,
day = "18",
doi = "10.1038/s41467-022-32265-5",
language = "English",
volume = "13",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort

AU - Aldridge, Robert W

AU - Yavlinsky, Alexei

AU - Nguyen, Vincent

AU - Eyre, Max T

AU - Shrotri, Madhumita

AU - Navaratnam, Annalan M D

AU - Beale, Sarah

AU - Braithwaite, Isobel

AU - Byrne, Thomas

AU - Kovar, Jana

AU - Fragaszy, Ellen

AU - Fong, Wing Lam Erica

AU - Geismar, Cyril

AU - Patel, Parth

AU - Rodger, Alison

AU - Johnson, Anne M

AU - Hayward, Andrew

PY - 2022/8/18

Y1 - 2022/8/18

N2 - A range of studies globally demonstrate that the effectiveness of SARS-CoV-2 vaccines wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection and whether this varies by vaccine type is not well understood. Here we show that anti-S levels peak three to four weeks following the second dose of vaccine and the geometric mean of the samples is nine fold higher for BNT162b2 than ChAdOx1. Increasing anti-S levels are associated with a reduced risk of SARS-CoV-2 infection (Hazard Ratio 0.85; 95%CIs: 0.79-0.92). We do not find evidence that this antibody relationship with risk of infection varies by second dose vaccine type (BNT162b2 vs. ChAdOx1). In keeping with our anti-S antibody data, we find that people vaccinated with ChAdOx1 had 1.64 times the odds (95% confidence interval 1.45-1.85) of a breakthrough infection compared to BNT162b2. We anticipate our findings to be useful in the estimation of the protective effect of anti-S levels on risk of infection due to Delta. Our findings provide evidence about the relationship between antibody levels and protection for different vaccines and will support decisions on optimising the timing of booster vaccinations and identifying individuals who should be prioritised for booster vaccination, including those who are older, clinically extremely vulnerable, or received ChAdOx1 as their primary course. Our finding that risk of infection by anti-S level does not interact with vaccine type, but that individuals vaccinated with ChAdOx1 were at higher risk of infection, provides additional support for the use of using anti-S levels for estimating vaccine efficacy. [Abstract copyright: © 2022. The Author(s).]

AB - A range of studies globally demonstrate that the effectiveness of SARS-CoV-2 vaccines wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection and whether this varies by vaccine type is not well understood. Here we show that anti-S levels peak three to four weeks following the second dose of vaccine and the geometric mean of the samples is nine fold higher for BNT162b2 than ChAdOx1. Increasing anti-S levels are associated with a reduced risk of SARS-CoV-2 infection (Hazard Ratio 0.85; 95%CIs: 0.79-0.92). We do not find evidence that this antibody relationship with risk of infection varies by second dose vaccine type (BNT162b2 vs. ChAdOx1). In keeping with our anti-S antibody data, we find that people vaccinated with ChAdOx1 had 1.64 times the odds (95% confidence interval 1.45-1.85) of a breakthrough infection compared to BNT162b2. We anticipate our findings to be useful in the estimation of the protective effect of anti-S levels on risk of infection due to Delta. Our findings provide evidence about the relationship between antibody levels and protection for different vaccines and will support decisions on optimising the timing of booster vaccinations and identifying individuals who should be prioritised for booster vaccination, including those who are older, clinically extremely vulnerable, or received ChAdOx1 as their primary course. Our finding that risk of infection by anti-S level does not interact with vaccine type, but that individuals vaccinated with ChAdOx1 were at higher risk of infection, provides additional support for the use of using anti-S levels for estimating vaccine efficacy. [Abstract copyright: © 2022. The Author(s).]

KW - Viral Vaccines

KW - COVID-19 Vaccines

KW - Humans

KW - Antibodies, Viral

KW - SARS-CoV-2

KW - BNT162 Vaccine

KW - COVID-19 - prevention & control

U2 - 10.1038/s41467-022-32265-5

DO - 10.1038/s41467-022-32265-5

M3 - Journal article

C2 - 35982056

VL - 13

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4869

ER -